New Phase 1/2 Trial Combines Tagmokitug and Pasritamig to Overcome Immune Suppression in Prostate Cancer
A new Phase 1/2 clinical trial will investigate an innovative immunotherapy combination involving tagmokitug (CHS-114) and pasritamig in men with metastatic castration-resistant prostate cancer (mCRPC). The study, known as TREGCHECK 103, aims to determine whether removing immune-suppressing cells from the tumor microenvironment can enhance the effectiveness of T-cell-engaging therapies.
Pasritamig is a bispecific antibody that simultaneously binds KLK2, a protein associated with prostate cancer cells, and CD3, a receptor on T cells. This interaction brings immune cells into close contact with cancer cells, triggering an immune attack. Tagmokitug works differently: it targets CCR8, a receptor expressed by certain regulatory T cells (Tregs), which can suppress antitumor immune responses. By selectively depleting CCR8-positive Tregs, tagmokitug is designed to make the tumor microenvironment more favorable to immune activity.
The combination therefore addresses two distinct challenges: recruiting T cells to attack prostate cancer and reducing the immune suppression that may limit their effectiveness. This strategy differs from the recently reported combination of pasritamig and JNJ-87189401, which attempts to strengthen T-cell activation through CD28 costimulation. Both approaches aim to enhance T-cell engagement, but through different biological mechanisms.
TREGCHECK 103 is an open-label, single-arm study planning to enroll approximately 12 patients. Eligible participants must have mCRPC previously treated with androgen receptor pathway inhibitors and taxane chemotherapy, with certain exceptions. The trial focuses on patients with bone and/or lymph node metastases without visceral involvement.
Clinical trial

Leave a Reply
Want to join the discussion?Feel free to contribute!